Premium
An oxaliplatin‐based chemotherapy in patients with relapsed or refractory intermediate and high‐grade non‐Hodgkin's lymphoma
Author(s) -
Chau Ian,
Webb Andrew,
Cunningham David,
Hill Mark,
Rao Sheela,
Ageli Suad,
Norman Andrew,
Gill Kairen,
Howard Anne,
Catovsky Daniel
Publication year - 2001
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2001.03181.x
Subject(s) - medicine , oxaliplatin , cytarabine , gastroenterology , regimen , neutropenia , chemotherapy , toxicity , surgery , oncology , cancer , colorectal cancer
This study was designed to assess the efficacy and safety of substituting cisplatin with oxaliplatin in the DHAP (dexamethasone, cytarabine and cisplatin) regimen for patients with relapsed or refractory non‐Hodgkin's lymphoma. Twenty‐four evaluable patients with intermediate or high‐grade non‐Hodgkin's lymphoma were treated at 3‐weekly intervals with oxaliplatin (130 mg/m 2 , d 1), cytarabine (2 g/m 2 for two doses, d 2) and dexamethasone (40 mg, d 1–4). The median age of the patients was 58 (range 18–70). Histological subtypes were diffuse large B cell, 20; mantle cell, two; anaplastic large cell, one; and peripheral T cell, one. The overall objective response rate (RR) was 50% [95% confidence interval (CI) = 29–71%] including four complete responses and eight partial responses. RR for those patients treated at first relapse was higher than those treated at second and subsequent relapse (77% versus 29%). Grade 3 and 4 toxicity was mainly haematological: anaemia 17%, neutropenia 75% and thrombocytopenia 75%. No grade 4 non‐haematological toxicity was reported. No significant renal and neurotoxicity was demonstrated. Median survival was 10·6 months. Probabilities of 1‐year progression‐free survival and overall survival were 47% (95% CI = 26–66%) and 50% (95% CI = 23–72%) respectively. In conclusion, dexamethasone, cytarabine and oxaliplatin (DHAX) is a novel combination in salvage therapy for relapsed or refractory non‐Hodgkin's lymphoma. It has clinically significant activity with an acceptable toxicity profile. Lack of renal toxicity makes DHAX an attractive cytoreductive regimen before high‐dose chemotherapy.